GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality
GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA’s recent approval for Moderna’s mRNA flu vaccine.
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality Read More »
